Nasdaq

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA ...

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, ...
Seeking Alpha

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death ...
manilatimes

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...
Nasdaq

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Nitasha Sarswat, M.D. of UChicago Medicine, ...